Chenglin Han

403 total citations
22 papers, 280 citations indexed

About

Chenglin Han is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Chenglin Han has authored 22 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Chenglin Han's work include Ferroptosis and cancer prognosis (5 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Renal cell carcinoma treatment (3 papers). Chenglin Han is often cited by papers focused on Ferroptosis and cancer prognosis (5 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Renal cell carcinoma treatment (3 papers). Chenglin Han collaborates with scholars based in China, South Korea and Japan. Chenglin Han's co-authors include Zilong Wang, Yingkun Xu, Xunbo Jin, Muwen Wang, Jianyi Li, Qinghua Xia, Guangzhen Wu, Yuqing Han, Lin Li and Lin Li and has published in prestigious journals such as Frontiers in Immunology, Journal of Ethnopharmacology and European Journal of Pharmacology.

In The Last Decade

Chenglin Han

22 papers receiving 278 citations

Peers

Chenglin Han

PRM

ONCOL

SURGE

Feng-Mei Zhou China

Aiping Yin China

Peichun Sun China

Yutong Meng China

Yiming Xu China

Xiaozhou Zou China

Haishi Zheng China

Xue Zhao China

Yuanwei Li China

Xiaoming Shi China

Feng-Mei Zhou China

Chenglin Han

127 ×0.9

82 ×0.9

60 ×0.8

PRM

53 ×1.5

ONCOL

20 ×0.6

SURGE

Citations per year, relative to Chenglin Han Chenglin Han (= 1×) peers Feng-Mei Zhou

Countries citing papers authored by Chenglin Han

Since Specialization

Citations

This map shows the geographic impact of Chenglin Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenglin Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenglin Han more than expected).

Fields of papers citing papers by Chenglin Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenglin Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenglin Han. The network helps show where Chenglin Han may publish in the future.

Co-authorship network of co-authors of Chenglin Han

This figure shows the co-authorship network connecting the top 25 collaborators of Chenglin Han. A scholar is included among the top collaborators of Chenglin Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenglin Han. Chenglin Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Chenglin, Bin Yang, Bintao Hu, et al.. (2025). Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15. Chinese Medicine. 20(1). 35–35. 1 indexed citations

Hu, Peng, Kang Liu, Wenchao Xu, et al.. (2024). MiRNA‐100 ameliorates diabetes mellitus‐induced erectile dysfunction by modulating autophagy, anti‐inflammatory, and antifibrotic effects. Andrology. 12(6). 1280–1293. 11 indexed citations

Li, Qinyu, Kai Zeng, Chenglin Han, et al.. (2024). Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2α. Autophagy. 21(3). 619–638. 8 indexed citations

Hu, Bintao, Chengwei Wang, Chenglin Han, et al.. (2024). Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics. Journal of Ethnopharmacology. 330. 118228–118228. 4 indexed citations

Han, Chenglin, et al.. (2024). Research on 3D Modeling Digital Twin Technology Based on Kraftwerk-Kennzeichen-System Coding for Hydropower Stations. 358–364. 1 indexed citations

Han, Chenglin, et al.. (2023). Modeling joint eating-out destination choices incorporating group-level impedance: A case study of the Greater Tokyo Area. Journal of Transport Geography. 111. 103672–103672. 4 indexed citations

Liu, Feifan, Keqin Zhang, Lianjun Li, et al.. (2023). High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application. Journal of Cancer Research and Therapeutics. 19(4). 945–950. 1 indexed citations

Han, Chenglin, Bin Yang, Peng Hu, et al.. (2023). Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer. Frontiers in Immunology. 14. 1126902–1126902. 5 indexed citations

Han, Chenglin, Jinwei Yang, Fei Yang, et al.. (2023). Comprehensive Transcriptome Analysis of Responses during Cold Stress in Wheat (Triticum aestivum L.). Genes. 14(4). 844–844. 13 indexed citations

10.

Han, Chenglin, Peng Hu, Bintao Hu, et al.. (2023). Comparison of cytokine levels in prostatic secretion between the IIIa and IIIb subtypes of prostatitis. Asian Journal of Andrology. 26(1). 77–84. 4 indexed citations

11.

Han, Chenglin, Yuxuan Deng, Wenchao Xu, et al.. (2022). The Roles of Tumor-Associated Macrophages in Prostate Cancer. Journal of Oncology. 2022. 1–20. 30 indexed citations

12.

Han, Chenglin, Zilong Wang, Lin Li, et al.. (2021). Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF‐κB Axis. Oxidative Medicine and Cellular Longevity. 2021(1). 8851763–8851763. 27 indexed citations

13.

Li, Lifeng, Zhaobao Wang, Chenglin Han, et al.. (2021). Optimal reference genes for real‐time quantitative PCR and the expression of sigma factors in Acidithiobacillus caldus under various conditions. Journal of Applied Microbiology. 131(4). 1800–1812. 1 indexed citations

14.

Han, Chenglin, et al.. (2021). RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway. OncoTargets and Therapy. Volume 14. 1643–1657. 16 indexed citations

15.

Wang, Zilong, Chenglin Han, Yingkun Xu, et al.. (2021). The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette–Guérin vaccine therapy in patients with nonmuscle invasive bladder cancer. Journal of Cancer Research and Therapeutics. 17(3). 625–629. 8 indexed citations

16.

Wang, Baojie, et al.. (2021). A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors. Neuropsychiatric Disease and Treatment. Volume 17. 99–110. 8 indexed citations

17.

Han, Chenglin, Zilong Wang, Yingkun Xu, et al.. (2020). Roles of Reactive Oxygen Species in Biological Behaviors of Prostate Cancer. BioMed Research International. 2020(1). 1269624–1269624. 39 indexed citations

18.

Xu, Yingkun, Xiunan Li, Yuqing Han, et al.. (2020). A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma. PPAR Research. 2020. 1–13. 21 indexed citations

19.

Wu, Guangzhen, Yingkun Xu, Qifei Wang, et al.. (2019). FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma. European Journal of Pharmacology. 862. 172637–172637. 34 indexed citations

20.

Han, Chenglin, et al.. (2019). A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis. Journal of Cancer. 11(4). 781–787. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact